Sign in

AKTS on Nasdaq

Aktis Oncology, Inc.

American pharmaceutical preparations company based in Boston1

In its 2026 annual report the company says: “We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.”3 Its shares trade on Nasdaq under the symbol AKTS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerAKTS on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address17 Drydock Avenue, Suite #17-401, Boston, Ma 022102
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Aktis Oncology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aktis Oncology, Inc.

  • Aktis Oncology, Inc. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aktis Oncology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our principal facilities consist of office and laboratory space. Our corporate headquarters is located in Boston, Massachusetts, where we lease and occupy approximately 17,944 square feet of such laboratory and office space at 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210. The current term of our lease expires in January 2033. We also lease an aggregate of 12,089 square feet of laboratory and office space in two facilities in Durham, North Carolina, under leases that expire in April 2027 and September 2026. We sublease approximately 1,332 square feet of such laboratory and office space.

We believe these facilities are adequate for the foreseeable future and that suitable additional space will be available as and when needed. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Aktis Oncology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Matthew Roden2026–now

President

  1. Matthew Roden2026–now

Chief financial officer

  1. Kyle D. Kuvalanka2026–now

Chief operating officer

  1. Shulamit Ron-Bigger2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorAndrew S. Levin named Oct 2, 202415
  • DirectorTodd Foley named Oct 2, 202415

Timeline

  1. Aug 13, 20268-K Results of operations16
  2. May 11, 20268-K Results of operations17
  3. Apr 16, 20268-K Executive or director change; Regulation FD disclosure18
  4. Mar 30, 20268-K Results of operations19
  5. Jan 12, 20268-K Bylaws or fiscal year changed20
  6. Jan 8, 2026New chief executive Matthew Roden becomes CEO4

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202621

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results16
  2. May 11, 2026Reported quarterly or annual results17
  3. Mar 30, 2026Reported quarterly or annual results19

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

62 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 5 major events, 30 insider forms, 5 large holders, 1 private raises, 18 other. The latest 20:

  1. Sep 24, 20264 EDGAR
  2. Sep 23, 2026144 EDGAR
  3. Aug 13, 202610-Q EDGAR
  4. Aug 13, 20268-K EDGAR
  5. Jul 21, 20264 EDGAR
  6. Jul 20, 2026144 EDGAR
  7. Jul 20, 20264 EDGAR
  8. Jul 17, 2026144 EDGAR
  9. Jul 10, 20264 EDGAR
  10. Jul 10, 20264 EDGAR
  11. Jul 8, 2026144 EDGAR
  12. Jul 8, 2026144 EDGAR
  13. May 14, 2026SCHEDULE 13G EDGAR
  14. May 11, 202610-Q EDGAR
  15. May 11, 20268-K EDGAR
  16. Apr 16, 20264 EDGAR
  17. Apr 16, 20263 EDGAR
  18. Apr 16, 20268-K EDGAR
  19. Mar 30, 20268-K EDGAR
  20. Mar 30, 202610-K EDGAR

The 62 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 6 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 23, 2026Czibere AkosChief Medical OfficerSale12,500$20.69$258.6KForm 4
Jul 20, 2026Herrmann KenDirectorSale4,856$24.56$119.3KForm 4
Jul 17, 2026Herrmann KenDirectorSale3,065$25.21$77.3KForm 4
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSale50,000$27.75$1.4MForm 4
Jul 8, 2026Czibere AkosChief Medical OfficerSale50,000$27.77$1.4MForm 4
Jan 12, 2026Foley ToddDirectorBuy232,870$18.00$4.2MForm 4
Jan 12, 2026MPM ONCOLOGY INNOVATIONS FUND LP10% ownerBuy1,112,777$18.00$20.0MForm 4
Jan 12, 2026GADICKE ANSBERT10% ownerBuy1,112,777$18.00$20.0MForm 4
Jan 12, 2026VIDA VENTURES II-A, LLC10% ownerBuy835,000$18.00$15.0MForm 4
Jan 12, 2026Kim Helen SusanDirectorBuy835,000$18.00$15.0MForm 4
Jan 12, 2026NODELMAN OLEGDirectorBuy2,222,222$18.00$40.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 20, 2024Raised $175 million in a private offering of equity Form D: 39 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mpm Bioimpact LLC4,835,872$155.9M9.5%No change
EcoR1 Capital, LLC4,824,469$155.5M7.7%No change
Blue Owl Capital Holdings LP3,070,219$99.0M15.0%−91,129
BlackRock, Inc.2,278,358$73.4M0.0%+166,231
Wellington Management Group Llp1,966,244$63.4M0.0%−350,800
Rtw Investments, LP1,592,043$51.3M0.4%No change
Ra Capital Management, L.P.1,314,405$42.4M0.4%−188,679
Jupiter Topco LLC1,314,267$42.4M0.0%New
Baker Bros. Advisors LP996,351$32.1M0.2%No change
Octagon Capital Advisors LP960,847$31.0M2.8%No change
Merck & Co., Inc.952,844$30.7M5.8%No change
Vanguard Capital Management LLC817,075$26.3M0.0%−16,838
TCG Crossover Management, LLC696,560$22.5M0.5%New
Geode Capital Management, LLC520,737$16.8M0.0%+28,801
Eventide Asset Management, LLC507,000$16.3M0.2%No change
Avidity Partners Management LP484,200$15.6M2.5%−452,932
State Street Corp484,010$15.6M0.0%+55,757
a16z Capital Management, L.L.C.415,000$13.4M0.1%No change
Alyeska Investment Group, L.P.290,000$9.3M0.0%No change
Fmr LLC285,631$9.2M0.0%−100,748
ArrowMark Colorado Holdings LLC245,872$7.9M0.3%−83,599
Northern Trust Corp180,575$5.8M0.0%+31,099
Charles Schwab Investment Management Inc166,842$5.4M0.0%+4,825
Barclays PLC151,696$4.9M0.0%+141,972
Vanguard Portfolio Management LLC145,220$4.7M0.0%+24,898

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Aktis Oncology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAktis Oncology, Inc.1
  • CIK0002035832
  • Employer ID (EIN)85-25842331
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address17 Drydock Avenue, Suite #17-401, Boston, MA 022101
  • Phone978-237-43801
  • On EDGAR sinceOct 2, 20241
  • Filings62 in all: 3 (17), 4 (13), 144 (5), 8-K (5), DRS/A (4), SCHEDULE 13D (4), 10-Q (2), S-1/A (2)1
    All 18 form types

    10-K (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), DRS (1), EFFECT (1), S-1 (1), S-8 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Latest 8-K (8-K) Aug 13, 2026

Risk factors and legal proceedings

The risks Aktis Oncology, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 74 risks under these headings, as written.3

  • Risks related to our limited operating history, financial condition and need for additional capital
  • We have incurred significant losses since our inception, have no products approved for sale, and we expect to incur losses for the foreseeable future.
  • Our limited operating history may make it difficult for you to evaluate our prospects and likelihood of success.
  • We will require additional funding to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we would be forced to delay, reduce, or eliminate our research and product candidate development programs.
  • We have not generated any revenue to date and may never be profitable.
  • Raising additional capital may cause dilution to our stockholders restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Risks related to our business and development of our product candidates
  • We are early in our development efforts. If we are unable to develop, and commercialize, any of our current or future product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.
  • Our business is highly dependent on our lead product candidate, [225Ac]Ac-AKY-1189, for the treatment of Nectin-4 expressing tumors. We must complete clinical trials before we can seek regulatory approval and begin commercialization of [225Ac]Ac-AKY-1189. If we are unable to obtain regulatory approval for, and successfully commercialize, [225Ac]Ac-AKY-1189, our business may be materially harmed, and such failure may affect our other current or future product candidates.
  • Preclinical and clinical development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If preclinical studies or clinical trials of a product candidate are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize [225Ac]Ac-AKY-1189, [225Ac]Ac-AKY-2519 or any of our future product candidates on a timely basis or at all.
  • Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of [225Ac]Ac-AKY-1189, [225Ac]Ac-AKY-2519, or any of our future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.
  • Our approach to the discovery and development of product candidates using our miniprotein radioconjugate platform represents a novel approach to radiation therapy, which may create significant and potentially unpredictable challenges for us.
The other 63 risks
  • Results of preclinical studies, dosimetry assessments, and early-stage clinical trials may not be predictive of the results of future preclinical studies or clinical trials.
  • Interim, topline, or preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available or as we make changes to our manufacturing processes and are subject to audit and verification procedures that could result in material changes in the final data.
  • Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition, results of operations and prospects. Additionally, disclosure of preliminary or interim data by us or by our competitors could result in volatility in the price of our common stock.
  • Due to the radioactive nature of our product candidates, once manufactured, our product candidates will have time-limited stability, and as a result, we may encounter difficulties with fulfilment and logistics.
  • We depend on enrollment and retention of patients in our clinical trials. If we experience delays or difficulties enrolling or retaining patients in our clinical trials, our research and development efforts and business, financial condition, results of operations and prospects could be materially adversely affected.
  • The commercial success of [225Ac]Ac-AKY-1189, or any of our other current or future products, if approved, will depend upon public perception of radiopharmaceuticals and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community.
  • We may develop [225Ac]Ac-AKY-1189, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.
  • The market opportunities for our product candidates may be smaller than we anticipated or may be limited to those patients who are ineligible for or have failed prior treatments. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Our company has never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining regulatory approval for our current and future product candidates.
  • We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved for commercial sale, we may not be able to generate product revenue.
  • We may become exposed to costly and damaging liability claims, either when testing [225Ac]Ac-AKY-1189 or our other current or future product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.
  • We are party to multiple license and collaboration agreements with significant payment obligations that are contingent upon the occurrence of future events, the timing and likelihood of which are difficult to predict. If we fail to comply with our obligations under these license and collaboration agreements, we could lose rights that are important to our business.
  • Risks related to government regulation
  • The development and commercialization of pharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for [225Ac]Ac-AKY-1189 or any other current or future product candidates, on a timely basis if at all, our business will be substantially harmed.
  • We may seek orphan drug designation for the product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • We may seek one or more designations or expedited programs for one or more of our product candidates, but we might not receive such designations or be allowed to proceed on expedited program pathways, and even if we do and proceed on such expedited program pathways in the future, such designations or expedited programs may not lead to a faster development or regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive marketing approval in the United States.
  • Even if [225Ac]Ac-AKY-1189 or any of our other current or future product candidates obtains regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, [225Ac]Ac-AKY-1189 or any of our other current or future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Disruptions at the FDA and other government agencies and foreign regulatory authorities, including those caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified drugs from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.
  • We are currently, and may in the future, conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
  • Our business operations and current and future relationships with healthcare professionals, principal investigators, consultants, vendors, customers, and third-party payors in the United States and elsewhere are subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings.
  • Healthcare policy changes may have a material adverse effect on our business, financial condition, results of operations and prospects.
  • Even if we are able to commercialize a product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
  • We and our collaborators and our third-party service providers are subject to a variety of stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and industry standards related to data privacy and cybersecurity, which could increase compliance costs, and our actual or perceived failure to comply therewith could subject us to regulatory investigations or actions, litigation, fines or penalties, disruptions of our business operation, reputational harm, loss of revenue or profits, and other adverse business consequences.
  • We are subject to certain U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
  • Risks related to manufacturing
  • We intend to build and operate our own manufacturing facility for preclinical and clinical supply needs, which will require significant resources, and we may fail to successfully establish and operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.
  • Our product candidates are biologics and the manufacture of our product candidates is complex. Even after our planned manufacturing facility is operating, we will continue to rely on third parties to manufacture our product candidates. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product supplies or product candidates, or fail to do so at acceptable quality levels or prices.
  • Our third-party manufacturers and clinical reagent suppliers may be subject to regulatory requirements or sanctions, as well as damage or interruption from, among other things, fire, natural or man-made disaster, power loss, telecommunications failure, unauthorized entry, computer viruses, denial-of-service attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events.
  • We may be unable to obtain a sufficient supply of 225Ac or other radioisotopes to support clinical development or manufacturing at commercial scale.
  • Changes in the methods of manufacturing or formulation of our product candidates may result in additional costs or delay.
  • Risks related to related to our dependence on third parties
  • We rely on third parties to conduct the Phase 1b clinical trial of [225Ac]Ac-AKY-1189 and plan to rely on third parties to conduct our future clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • We have in place certain collaboration and licensing arrangements, and may form or seek collaborations, strategic alliances or licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.
  • If we or third parties, such as CROs, CDMOs, CMOs, use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • Our employees, independent contractors, principal investigators, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • Risks related to intellectual property
  • We do not own or expect to own any issued patents relating to the radioactive payload, 225Ac, used in our product candidates, including [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519.
  • Our success depends on our ability to obtain, maintain, enforce, defend and protect our intellectual property and our proprietary technologies, and conduct our business without infringing, misappropriating or otherwise violating intellectual property or proprietary rights of others.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
  • We may not be able to obtain and protect our intellectual property rights throughout the world.
  • Obtaining, maintaining, enforcing, protecting and defending our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our current or future licensors and the enforcement or defense of our future issued patents or those of our current or future licensors.
  • If we do not obtain patent term extension for our product candidates, our business may be materially harmed.
  • We may license technology from third parties that may be subject to retained rights, including certain intellectual property discovered through government funded programs that is subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • We cannot ensure that patent rights relating to inventions described and claimed in our and our licensors’ pending patent applications will issue or that patents based on our or our licensors’ patent applications will not be challenged and rendered invalid and/or unenforceable.
  • We may be involved in lawsuits to protect or enforce any patents we obtain in the future or our future licensors’ patents, which could be expensive, time consuming and unsuccessful. Further, any future issued patents we obtain or our current or future licensors’ patents could be found invalid or unenforceable if challenged in court.
  • Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights, including patents, of third parties. Claims by third parties that we infringe, misappropriate, or otherwise violate their intellectual property or other proprietary rights, may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed.
  • We may be subject to claims that we or our employees, consultants, or collaborators have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers or claims asserting ownership of what we regard as our own intellectual property.
  • Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights to or from third parties or otherwise experience disruptions to our business relationships with our current and future licensors or licensees, we could lose license rights that are important to our business.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • The use of new and evolving technologies, such as AI, in our operations may require us to expend material resources and may present risks and challenges that can impact our business, including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or otherwise adversely affect our business.
  • Risks related to Employee Matters and Managing Growth
  • Our ability to develop our future product candidates for our future growth depends on retaining our key personnel and recruiting additional qualified personnel.
  • We expect to continue to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our insurance policies are expensive and protect us from only some business risks, which will leave us exposed to significant uninsured liabilities.

Legal proceedings

From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We are not currently subject to any material legal or arbitration proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26